DRI Healthcare Trust (DHT-UN) Q3 2025 earnings summary

Executive summary

• Achieved strong Q3 results with double-digit growth in cash receipts, income, and adjusted EBITDA, led by Orserdu, Xolair, and Rydapt, and supported by portfolio diversification and resilient cashflow streams.

• Completed internalization of investment management, paying a $48 million termination fee and acquiring assets from Persis Capital for $1 million.

• Completed a synthetic royalty transaction on veligrotug and VRDN-003 for up to $300 million, with $55 million upfront and up to $115 million in milestone payments, expanding exposure to the TED market.

• Continued execution of NCIB program, repurchasing over 4.5 million units as of September 30, 2025, to enhance unitholder value.

• EKTERLY approval in July marked a milestone, with royalties beginning on a one-quarter lag and a $22 million payment increasing royalty entitlement.

Financial highlights

• Q3 2025 total cash receipts: $43.6 million, up 12% year-over-year; total income: $48.7 million, up 17% year-over-year.

• Adjusted EBITDA: $36.7 million (84% margin), up 17% year-over-year; last twelve months adjusted EBITDA: $155.7 million (82% margin).

• Adjusted cash earnings per unit: $0.55 for Q3 2025; $2.25 for the last 12 months.

• Cash and equivalents: $35.6 million; royalties receivable: $52.9 million; credit facility availability: $265.4 million as of September 30, 2025.

• Declared cash distributions of $0.10 per unit for the quarter.

Outlook and guidance

• Robust pipeline of over $3 billion in potential opportunities under active evaluation as of September 30, 2025.

• Guidance for total income CAGR to be updated in Q4, with management expressing confidence in current trajectory.

• Anticipates first royalty receipts from veligrotug following its first US commercial sale and expects topline results from VRDN-003 phase 3 trials in H1 2026.

• Expects gradual recovery in Omidria sales into 2026 and continued growth for Vonjo, despite impairment.

• Focus remains on long-term, sustainable growth and generating strong unitholder returns.